About the Show
The Australasian Melanoma Conference is a specialist medical and scientific conference dedicated to improving outcomes for people affected by melanoma and other skin cancers.
Taking place at Sofitel Melbourne on Collins, AMC 2026 will examine new discoveries in basic science alongside emerging approaches to melanoma prevention, early detection, diagnosis and clinical management. The conference is designed to encourage knowledge exchange between researchers, clinicians, healthcare professionals, consumers and organisations supporting melanoma care.
The multidisciplinary program addresses the complete patient journey—from prevention and screening through to advanced disease, immunotherapy, survivorship and consumer-centred care.
Key Features of the Show
Multidisciplinary scientific program
The conference program is structured around four principal categories:
- Prevention
- Early Detection
- Advanced Disease
- Survivorship
These themes are explored through plenary sessions, concurrent presentations, panel discussions, workshops and oral abstract presentations.
International and Australian speakers
AMC 2026 has announced invited speakers from organisations including Oxford University Hospitals, Harvard Medical School, the University of California San Francisco, Cancer Research UK, Melanoma Institute Australia, Cancer Australia, QIMR Berghofer, Peter MacCallum Cancer Centre and other leading institutions.
Abstract and research presentations
The conference supports both oral and poster presentations across areas including screening, diagnosis, prognosis, tumour biology, melanoma therapy, imaging, survivorship and less common melanoma subtypes. Late-breaking abstract submissions are open until 14 August 2026.
Professional networking
The conference includes a welcome networking reception and a conference dinner at the Melbourne Cricket Ground, creating opportunities for delegates, speakers, researchers and industry representatives to build professional connections outside the scientific sessions.
Who Should Exhibit?
AMC 2026 is particularly relevant for organisations working across:
- Pharmaceutical and biopharmaceutical products
- Oncology and immunotherapy
- Dermatology and skin cancer treatment
- Medical imaging, dermoscopy and mole-mapping systems
- Artificial intelligence and diagnostic software
- Pathology and laboratory services
- Genomics, biomarkers and precision medicine
- Clinical trial services and research networks
- Surgical equipment and medical devices
- Photoprotection, sunscreen and therapeutic skincare
- Nursing, allied health and patient-care solutions
- Medical education and professional associations
- Consumer advocacy and patient-support organisations
- Healthcare data, digital platforms and clinical systems
Who Attends?
AMC 2026 is designed for a multidisciplinary audience that includes:
- Dermatologists
- Medical and surgical oncologists
- General practitioners and skin cancer physicians
- Surgeons
- Anatomical pathologists
- Radiologists and imaging professionals
- Nurses and allied health professionals
- Clinical researchers and senior scientists
- Immunology and tumour-biology researchers
- Epidemiologists and public-health professionals
- Postdoctoral researchers and medical trainees
- Higher-degree and full-time students
- Pharmaceutical and healthcare industry professionals
- Clinical trial organisations
- Consumer representatives and patient advocates
- Healthcare policy and cancer-control professionals
Why Should You Exhibit?
Reach a highly specialised audience
Exhibitors can meet professionals directly involved in melanoma prevention, diagnosis, treatment, clinical trials, research and long-term patient care.
Support scientific and clinical education
Participation positions an organisation alongside discussions addressing artificial intelligence, immunotherapy, biomarkers, screening, pathology, photoprotection, survivorship and emerging treatment models.
Increase brand visibility
Exhibition and sponsorship packages provide opportunities to establish brand presence, introduce new products, support educational activities and strengthen recognition within the Australasian melanoma community.
Develop research and industry partnerships
AMC 2026 provides a platform for conversations around clinical trials, research collaborations, product development, education and the translation of scientific discoveries into clinical practice.
